Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
Vered Stearns(Johns Hopkins University), Anil A. Joy(University of Alberta), Dongrui R. Lu(Pfizer (United States)), Matthew J. Cotter(Pfizer (United States)), Shailendra Verma(University of Lucknow), Florence Dequen(Centre hospitalier de l'Université Laval), Adam Brufsky(University of Pittsburgh)
Cited by 22
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment
|JNCI Journal of the National Cancer Institute|2005|947
Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine
|JNCI Journal of the National Cancer Institute|2003|850